ClinicalTrials.gg
RecruitingNCT07540572Updated Nov 5, 2026

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

A Phase 1 interventional study of IDE574 and Fulvestrant injection in Cancer, sponsored by IDEAYA Biosciences. Recruiting at 23 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by IDEAYA Biosciences · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 5, 2026First site in GeorgiaPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.

The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.

Read the detailed description

Part 1 - Monotherapy Dose Escalation and Expansion:

Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.

Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.

Part 1C - Exploratory Food Effect Sub-study

Part 2 - Combination Dose Escalation and Expansion

Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.

Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • KAT6A/B
  • KAT7
03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 155 is above the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

IDEAYA Biosciences is the lead sponsor of 11 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

sample for testing

  • Part 1A - Participants with advanced or cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
  • Female participants with cancer considered to be of (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
  • Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age \<60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
  • Have performance status (ECOG PS) of ≤1.
  • Have adequate bone marrow, renal and liver function.
  • of >3 months
  • Able to safely administer and retain orally administered study treatment
  • Able to comply with /barrier requirements

Key Exclusion Criteria:

  • Known symptomatic or
  • Known primary CNS and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
  • Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
  • Have active liver or biliary disease.
  • Have active, uncontrolled bacterial, fungal, or viral infection
  • Have cardiac abnormalities and/or blood clotting events within 6 months before the first dose
  • If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
  • Prior irradiation to >25% of the bone marrow.
  • Known or suspected to IDE574/ or components (Parts 1 \& 2) or fulvestrant/excipients or components (Part 2 only)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
155 participants (estimated)

Study arms

  • Experimental
    Monotherapy Dose Escalation (Part 1A)

    Participants with the appropriate tumor types will be treated with escalating doses of IDE574

    Drug: IDE574

  • Experimental
    Monotherapy Dose Expansion (Part 1B)

    Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574

    Drug: IDE574

  • Experimental
    Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant

    Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant

    Drug: IDE574 · Drug: Fulvestrant injection

  • Experimental
    Combination Dose Expansion (Part 2B)

    Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant

    Drug: IDE574 · Drug: Fulvestrant injection

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation

    incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0

    Time frame: Following the first dose of IDE574

  2. Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs

    Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

    Time frame: total study duration

  3. To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1

    Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

    Time frame: total study duration

  4. To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.

    Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

    Time frame: total study duration

  5. Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT

    Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0

    Time frame: total study duration

  6. Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs

    Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

    Time frame: total study duration

  7. Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1

    Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

    Time frame: total study duration

  8. Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.

    Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

    Time frame: total study duration

Secondary outcomes

  1. Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1

    Time frame: total study duration

  2. Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.

    Time frame: total study duration

  3. Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)

    Time frame: total study duration

  4. Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate

    Time frame: total study duration

  5. Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation

    Time frame: total study duration

  6. Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion

    Time frame: total study duration

  7. Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion

    Time frame: total study duration

  8. Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types

    Time frame: total study duration

  9. Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1

    Time frame: total study duration

  10. Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1

    Time frame: total study duration

  11. Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1

    Time frame: total study duration

  12. Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation

    Time frame: total study duration

  13. Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1

    Time frame: total study duration

  14. Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion

    Time frame: total study duration

07

Study locations

18 of 23 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2029, 45 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 45 months is above that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Mar 2030 → Dec 2029 and completion Jun 2030 → Jan 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 20, 2026
StartActual
Mar 17, 2026
Primary completionEst.
Dec 31, 2029was Mar 2030
CompletionEst.
Jan 31, 2030was Jun 2030
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added — first site in Georgia
Show 12 added (7 United States, 5 Georgia)
  • UCLA - Parkside Cancer Center · Santa Monica, United States
  • Yale School of Medicine - Cedar Street · New Haven, United States
  • Winship Cancer Institute, Emory University · Atlanta, United States
  • Washington University - Siteman Cancer Center · St Louis, United States
  • Columbia University Medical Center -161 Fort Washington · New York, United States
  • SCRI Oncology Partners - PPDS · Nashville, United States
  • MD Anderson Cancer Center · Houston, United States
  • High Technology Hospital MedCenter Ltd · Batumi, Georgia
  • LLC ARENSIA Exploratory Medicine · Tbilisi, Georgia
  • Pineo Medical Ecosystem · Tbilisi, Georgia
  • Geo Hospitals Multiprofile Medical Center Tbilisi · Tbilisi, Georgia
  • LLC Caucasus Medical Centre · Tbilisi, Georgia
Nov 5, 2026
Primary completion
Mar 30, 2030→Dec 31, 2029
Nov 5, 2026
Study completion
Jun 30, 2030→Jan 31, 2030
Nov 5, 2026
Enrollment
160→155
Nov 5, 2026
Eligibility
3 criteria edited, 1 removed
What changed in the criteria
  • EditedPart 1A - Participants with advanced or metastatic ER+, HER2- breast cancer, NSCLC, CRPC, and MSS colorectal adenocarcinoma who have progressed on/after at least one line of standard of care therapy or are intolerant to additional effective therapies.
  • RemovedParts 1B, 2A and 2B: Participants with ER+, HER2- breast cancer who have progressed after at least 1 prior line of treatment with an endocrine therapy and a CDK4/6 inhibitor
  • EditedFemale participants with ER+, HER2- breast cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
  • EditedFemale participants of nonchildbearing potential with ER+, HER2- breast cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
Nov 5, 2026
Primary outcomes
2 edited, 6 time frame changed
What changed in the outcomes
  • EditedTo evaluate anti-tumor activity of IDE574 of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1Time frame: Approximately 24 months total study duration → total study duration
  • EditedTo evaluate anti-tumor activity of IDE574 of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.Time frame: Approximately 24 months total study duration → total study duration
  • Time frameSafety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation21 days following the first dose of IDE574 → Following the first dose of IDE574
  • Time frameSafety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEsApproximately 24 months total study duration → total study duration
  • Time frameSafety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLTApproximately 24 months total study duration → total study duration
  • Time frameSafety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEsApproximately 24 months total study duration → total study duration
  • Time frameAnti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1Time Frame: Approximately 24 months total study duration → total study duration
  • Time frameAnti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.Time Frame: Approximately 24 months total study duration → total study duration
Nov 5, 2026
Secondary outcomes
1 edited, 13 time frame changed, 16 removed, 13 more
What changed in the outcomes
  • EditedEvaluate the pharmacokinetics (PK)antitumor activity of IDE574 in Part 1A1B Monotherapy Dose EscalationExpansionTime frame: Approximately 24 months total study duration → total study duration
  • RemovedEvaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose EscalationTime frame: Approximately 24 months total study duration
  • RemovedEvaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose EscalationTime frame: Approximately 24 months total study duration
  • RemovedEvaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose EscalationTime frame: Approximately 24 months total study duration
  • RemovedEvaluate the PK of IDE574 in Part 1B Monotherapy Dose ExpansionTime frame: Approximately 24 months total study duration
  • RemovedEvaluate the PK of IDE574 in Part 1B Monotherapy Dose ExpansionTime frame: Approximately 24 months total study duration
  • RemovedEvaluate the PK of IDE574 in Part 1B Monotherapy Dose ExpansionTime frame: Approximately 24 months total study duration
  • RemovedEvaluate the PK of IDE574 in Part 1B Monotherapy Dose ExpansionTime frame: Approximately 24 months total study duration
  • RemovedEvaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on CBR for ER+, HER2- breast cancerTime frame: Approximately 24 months total study duration
  • RemovedEvaluate the PK of IDE574 in Part 2A Combination Dose EscalationTime frame: Approximately 24 months total study duration
  • RemovedEvaluate the PK of IDE574 in Part 2A Combination Dose EscalationTime frame: Approximately 24 months total study duration
  • RemovedEvaluate the PK of IDE574 in Part 2A Combination Dose EscalationTime frame: Approximately 24 months total study duration
  • RemovedEvaluate the PK of IDE574 in Part 2A Combination Dose EscalationTime frame: Approximately 24 months total study duration
  • RemovedEvaluate the PK of IDE574 in Part 2B Combination Dose ExpansionTime frame: Approximately 24 months total study duration
  • RemovedEvaluate the PK of IDE574 in Part 2B Combination Dose ExpansionTime frame: Approximately 24 months total study duration
  • RemovedEvaluate the PK of IDE574 in Part 2B Combination Dose ExpansionTime frame: Approximately 24 months total study duration
  • RemovedEvaluate the PK of IDE574 in Part 2B Combination Dose ExpansionTime frame: Approximately 24 months total study duration
  • Time frameEvaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1Approximately 24 months total study duration → total study duration
  • Time frameEvaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.Approximately 24 months total study duration → total study duration
  • Time frameEvaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)Approximately 24 months total study duration → total study duration
  • Time frameEvaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rateApproximately 24 months total study duration → total study duration
  • Time frameEvaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose EscalationApproximately 24 months total study duration → total study duration
  • Time frameEvaluate the PK of IDE574 in Part 1B Monotherapy Dose ExpansionApproximately 24 months total study duration → total study duration
  • Time frameEvaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor typesApproximately 24 months total study duration → total study duration
  • Time frameEvaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1Approximately 24 months total study duration → total study duration
  • Time frameEvaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1Approximately 24 months total study duration → total study duration
  • Time frameEvaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1Approximately 24 months total study duration → total study duration
  • Time frameEvaluate the PK of IDE574 in Part 2A Combination Dose EscalationApproximately 24 months total study duration → total study duration
  • Time frameEvaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1Approximately 24 months total study duration → total study duration
  • Time frameEvaluate the PK of IDE574 in Part 2B Combination Dose ExpansionApproximately 24 months total study duration → total study duration
  • …and 13 more, on the record history on ClinicalTrials.gov ↗
Nov 5, 2026
Site contacts
Changed at 11 sites. See the sites
Show 11 sites
  • Florida Clinical Trials Group · Plantation, United StatesContact h•••@floridactg.com · •••9991→p•••@floridactg.com · •••3057Contact added (no phone or email listed)
  • START Astera, LLC · East Brunswick, United StatesContact added (no phone or email listed)
  • START New York Long Island, LLC · Lake Success, United StatesContact i•••@startresearch.com · •••5160→g•••@startresearch.com · •••5160Contact added (no phone or email listed)
  • NEXT Texas LLC - Austin · Austin, United StatesContact s•••@nextoncology.com · •••5200→n•••@nextoncology.com · •••5202Contact added (no phone or email listed)
  • NEXT Texas LLC - Dallas · Dallas, United StatesContact f•••@nextoncology.com · •••8800→N•••@nextoncology.com · •••9479Contact added (no phone or email listed)
  • START Dallas Fort Worth, LLC · Fort Worth, United StatesContact added (no phone or email listed)
  • NEXT Texas LLC - Houston · Houston, United StatesContact j•••@nextoncology.com · •••7900→n•••@nextoncology.com · •••9479Contact added (no phone or email listed)
  • NEXT Texas LLC - San Antonio · San Antonio, United StatesContact d•••@nextoncology.com · •••9500→N•••@nextoncology.com · •••9500Contact added (no phone or email listed)
  • Start San Antonio, LLC · San Antonio, United StatesContact i•••@startresearch.com · •••5250→H•••@startresearch.com · •••5700Contact added (no phone or email listed)
  • START Mountain Region, LLC · West Valley City, United StatesContact added (no phone or email listed)
  • NEXT Virginia · Fairfax, United StatesContact m•••@nextoncology.com · •••4510→n•••@nextoncology.com · •••4518Contact added (no phone or email listed)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    12 sites added — first site in Georgia
    Show 12 added (7 United States, 5 Georgia)
    • UCLA - Parkside Cancer Center · Santa Monica, United States
    • Yale School of Medicine - Cedar Street · New Haven, United States
    • Winship Cancer Institute, Emory University · Atlanta, United States
    • Washington University - Siteman Cancer Center · St Louis, United States
    • Columbia University Medical Center -161 Fort Washington · New York, United States
    • SCRI Oncology Partners - PPDS · Nashville, United States
    • MD Anderson Cancer Center · Houston, United States
    • High Technology Hospital MedCenter Ltd · Batumi, Georgia
    • LLC ARENSIA Exploratory Medicine · Tbilisi, Georgia
    • Pineo Medical Ecosystem · Tbilisi, Georgia
    • Geo Hospitals Multiprofile Medical Center Tbilisi · Tbilisi, Georgia
    • LLC Caucasus Medical Centre · Tbilisi, Georgia
    Primary completion Mar 30, 2030→Dec 31, 2029
    Study completion Jun 30, 2030→Jan 31, 2030
    Enrollment 160→155
    Eligibility 3 criteria edited, 1 removed
    What changed in the criteria
    • EditedPart 1A - Participants with advanced or metastatic ER+, HER2- breast cancer, NSCLC, CRPC, and MSS colorectal adenocarcinoma who have progressed on/after at least one line of standard of care therapy or are intolerant to additional effective therapies.
    • RemovedParts 1B, 2A and 2B: Participants with ER+, HER2- breast cancer who have progressed after at least 1 prior line of treatment with an endocrine therapy and a CDK4/6 inhibitor
    • EditedFemale participants with ER+, HER2- breast cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
    • EditedFemale participants of nonchildbearing potential with ER+, HER2- breast cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
    Primary outcomes 2 edited, 6 time frame changed
    What changed in the outcomes
    • EditedTo evaluate anti-tumor activity of IDE574 of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1Time frame: Approximately 24 months total study duration → total study duration
    • EditedTo evaluate anti-tumor activity of IDE574 of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.Time frame: Approximately 24 months total study duration → total study duration
    • Time frameSafety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation21 days following the first dose of IDE574 → Following the first dose of IDE574
    • Time frameSafety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEsApproximately 24 months total study duration → total study duration
    • Time frameSafety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLTApproximately 24 months total study duration → total study duration
    • Time frameSafety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEsApproximately 24 months total study duration → total study duration
    • Time frameAnti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1Time Frame: Approximately 24 months total study duration → total study duration
    • Time frameAnti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.Time Frame: Approximately 24 months total study duration → total study duration
    Secondary outcomes 1 edited, 13 time frame changed, 16 removed, 13 more
    What changed in the outcomes
    • EditedEvaluate the pharmacokinetics (PK)antitumor activity of IDE574 in Part 1A1B Monotherapy Dose EscalationExpansionTime frame: Approximately 24 months total study duration → total study duration
    • RemovedEvaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose EscalationTime frame: Approximately 24 months total study duration
    • RemovedEvaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose EscalationTime frame: Approximately 24 months total study duration
    • RemovedEvaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose EscalationTime frame: Approximately 24 months total study duration
    • RemovedEvaluate the PK of IDE574 in Part 1B Monotherapy Dose ExpansionTime frame: Approximately 24 months total study duration
    • RemovedEvaluate the PK of IDE574 in Part 1B Monotherapy Dose ExpansionTime frame: Approximately 24 months total study duration
    • RemovedEvaluate the PK of IDE574 in Part 1B Monotherapy Dose ExpansionTime frame: Approximately 24 months total study duration
    • RemovedEvaluate the PK of IDE574 in Part 1B Monotherapy Dose ExpansionTime frame: Approximately 24 months total study duration
    • RemovedEvaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on CBR for ER+, HER2- breast cancerTime frame: Approximately 24 months total study duration
    • RemovedEvaluate the PK of IDE574 in Part 2A Combination Dose EscalationTime frame: Approximately 24 months total study duration
    • RemovedEvaluate the PK of IDE574 in Part 2A Combination Dose EscalationTime frame: Approximately 24 months total study duration
    • RemovedEvaluate the PK of IDE574 in Part 2A Combination Dose EscalationTime frame: Approximately 24 months total study duration
    • RemovedEvaluate the PK of IDE574 in Part 2A Combination Dose EscalationTime frame: Approximately 24 months total study duration
    • RemovedEvaluate the PK of IDE574 in Part 2B Combination Dose ExpansionTime frame: Approximately 24 months total study duration
    • RemovedEvaluate the PK of IDE574 in Part 2B Combination Dose ExpansionTime frame: Approximately 24 months total study duration
    • RemovedEvaluate the PK of IDE574 in Part 2B Combination Dose ExpansionTime frame: Approximately 24 months total study duration
    • RemovedEvaluate the PK of IDE574 in Part 2B Combination Dose ExpansionTime frame: Approximately 24 months total study duration
    • Time frameEvaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1Approximately 24 months total study duration → total study duration
    • Time frameEvaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.Approximately 24 months total study duration → total study duration
    • Time frameEvaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)Approximately 24 months total study duration → total study duration
    • Time frameEvaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rateApproximately 24 months total study duration → total study duration
    • Time frameEvaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose EscalationApproximately 24 months total study duration → total study duration
    • Time frameEvaluate the PK of IDE574 in Part 1B Monotherapy Dose ExpansionApproximately 24 months total study duration → total study duration
    • Time frameEvaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor typesApproximately 24 months total study duration → total study duration
    • Time frameEvaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1Approximately 24 months total study duration → total study duration
    • Time frameEvaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1Approximately 24 months total study duration → total study duration
    • Time frameEvaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1Approximately 24 months total study duration → total study duration
    • Time frameEvaluate the PK of IDE574 in Part 2A Combination Dose EscalationApproximately 24 months total study duration → total study duration
    • Time frameEvaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1Approximately 24 months total study duration → total study duration
    • Time frameEvaluate the PK of IDE574 in Part 2B Combination Dose ExpansionApproximately 24 months total study duration → total study duration
    • …and 13 more, on the record history on ClinicalTrials.gov ↗
    Site contacts Changed at 11 sites. See the sites
    Show 11 sites
    • Florida Clinical Trials Group · Plantation, United StatesContact h•••@floridactg.com · •••9991→p•••@floridactg.com · •••3057Contact added (no phone or email listed)
    • START Astera, LLC · East Brunswick, United StatesContact added (no phone or email listed)
    • START New York Long Island, LLC · Lake Success, United StatesContact i•••@startresearch.com · •••5160→g•••@startresearch.com · •••5160Contact added (no phone or email listed)
    • NEXT Texas LLC - Austin · Austin, United StatesContact s•••@nextoncology.com · •••5200→n•••@nextoncology.com · •••5202Contact added (no phone or email listed)
    • NEXT Texas LLC - Dallas · Dallas, United StatesContact f•••@nextoncology.com · •••8800→N•••@nextoncology.com · •••9479Contact added (no phone or email listed)
    • START Dallas Fort Worth, LLC · Fort Worth, United StatesContact added (no phone or email listed)
    • NEXT Texas LLC - Houston · Houston, United StatesContact j•••@nextoncology.com · •••7900→n•••@nextoncology.com · •••9479Contact added (no phone or email listed)
    • NEXT Texas LLC - San Antonio · San Antonio, United StatesContact d•••@nextoncology.com · •••9500→N•••@nextoncology.com · •••9500Contact added (no phone or email listed)
    • Start San Antonio, LLC · San Antonio, United StatesContact i•••@startresearch.com · •••5250→H•••@startresearch.com · •••5700Contact added (no phone or email listed)
    • START Mountain Region, LLC · West Valley City, United StatesContact added (no phone or email listed)
    • NEXT Virginia · Fairfax, United StatesContact m•••@nextoncology.com · •••4510→n•••@nextoncology.com · •••4518Contact added (no phone or email listed)
    + 7 other changes: index terms, identifiers, verification date, description, conditions, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07540572
Lead sponsor
IDEAYA Biosciences
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Mar 17, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Nov 5, 2026

Study contacts

IDEAYA Clinical Trials
Contact
IDEAYAClinicalTrials@ideayabio.com
+1-855-433-224

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion